Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644068 · ClinicalTrials.gov registry record · Phase 1
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 702
- Enrollment target
- 20
- Study locations
NCT04644068: Active Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by AstraZeneca.
NCT04644068 is a Phase 1 study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 702 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04644068, a Phase 1 study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 702 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Primary Outcome
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Dato-DXd
- DRUG AZD5305
- DRUG T- Dxd
Study Locations (20)
Other
- Research Site - Heidelberg
- Research Site - Melbourne
- Research Site - Beijing
- Research Site - Changchun
- Research Site - Changsha
- Research Site - Chengdu
- Research Site - Chongqing
- Research Site - Guangzhou
- Research Site - Harbin
- Research Site - Jining
- Research Site - Shandong
Massachusetts
- Research Site - Boston
- Research Site - Boston
Quebec
- Research Site - Montreal
- Research Site - Montreal
New York
- Research Site - New York
Oklahoma
- Research Site - Oklahoma City
Texas
- Research Site - Houston
British Columbia
- Research Site - Vancouver
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 702 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2027-05-28 |
| Phase | Phase 1 |
What the registry record for NCT04644068 still lists
NCT04644068 is an interventional study that assigns participants to a tested intervention. The registered 702 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04644068 names 20 study sites across 8 states, led by Other, Massachusetts, Quebec.
Frequently Asked Questions
What is clinical trial NCT04644068 about?
NCT04644068 is a clinical study titled "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies". This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
What is the current status of trial NCT04644068?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 702 participants. The study started on 2020-11-12. Estimated completion is 2027-05-28.
What conditions does trial NCT04644068 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT04644068?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Dato-DXd (DRUG), AZD5305 (DRUG), T- Dxd (DRUG).
Who is sponsoring clinical trial NCT04644068?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04644068 being conducted?
This trial has 20 study locations across Massachusetts, New York, Oklahoma, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04644068's enrollment target sits among peer trials
702 159th of 1224 higher than 1,066 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI